Brief: Codiak Biosciences Reports Third Quarter 2020 Financial Results And Operational Progress
19/11/2020 21:21
Codiak BioSciences, Inc. CDAK.O :
* CODIAK BIOSCIENCES REPORTS THIRD QUARTER 2020 FINANCIAL
RESULTS
AND OPERATIONAL PROGRESS
* Q3 REVENUE $1.0 MILLION VERSUS $200,000
* CODIAK BIOSCIENCES - INITIAL SAFETY RESULTS AND
PRELIMINARY
SYSTEMIC EXPOSURE/PHARMACOKINETICS OF EXOIL-12 IN HEALTHY
VOLUNTEERS ANTICIPATED YE 2020
* BIOMARKER, SAFETY AND CLINICAL OUTCOME RESULTS IN CANCER
PATIENTS ANTICIPATED MID-2021 FOR BOTH EXOSTING AND EXOIL-12
* QTRLY LOSS PER SHARE $12.83
Source text for Eikon: ID:nGNX8k3WwZ
Further company coverage: CDAK.O
Recent news on Codiak BioSciences,.
See all newsBrief: Codiak Biosciences Notice From Listing Qualifications Department Of Nasdaq Trading Of Co's Common Stock To Be Suspended At Opening Of Business On April 5
U.S. STOCKS ON THE MOVE-Energy firms, crypto stocks, Walt Disney
U.S. STOCKS ON THE MOVE-Cyclerion, banks, Jounce Therapeutics
U.S. STOCKS ON THE MOVE-Tesla, BrainStorm, Pinterest
Codiak BioSciences down after co files for Chapter 11 bankruptcy